Johnson & Johnson Steps Up Medical Device Investment In China
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson, known in China for its personal care and infant products, has of late stepped up efforts in its medical device business. Now the firm's second largest portfolio-with sales overtaking drugs and consumables for the past five consecutive years-medical device sales and profit have surpassed 36 percent growth annually. The firm also plans to acquire local companies in the sector to rapidly penetrate into the medium- and low-end medical device business, widely regarded as the first segment to benefit from China's health care reform. Johnson & Johnson is in the process of buying domestic firm DaBao Daily Chemicals; if successful, the 2.3 billion yuan deal will be J&J's biggest acquisition in China. (Click here for more - Chinese language)
You may also be interested in...
J&J Opens Device Plant In Suzhou, Expects Larger Piece Of China’s Growing Device Market
BEIJING - Johnson & Johnson's medical device manufacturing base started operation in China's southern city of Suzhou, the company announced April 22
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.